Keros Therapeutics Inc (KROS)

$KROS - Keros Therapeutics Inc. Common Stock - 10Q - Updated Risk Factors Keros updates risk factors in 2025 emphasizing clinical and regulatory uncertainties for KER-065 and elritercept, dependence on key patents and collaborations, intensified IP litigation risks, manufacturing and trial outsourcing vulnerabilities, corporate restructuring costs, evolving tax and compliance burdens, stock volatility and shareholder concentration concerns, plus new anti-takeover provisions and potential limits on capital returns. #Biotechnology #CorporateRestructuring #RegulatoryRisk #IntellectualProperty #ClinicalTrials 🟢 Added 🟠 Removed https://d-risk.ai/KROS/10-Q/2025-08-06

$KROS when and how are we getting our $9. I would not be surprised to hear they have changed their minds.

$GNS $HOOD $AMC $GME $KROS

$KROS "Heads up alert! Upcoming earnings on Tuesday, 8/5/2025 for $KROS Neutral (5.2) Financial Analysis Keros Therapeutics (KROS) is positioned within the biotechnology sector, focusing on developing therapeutics for disorders related to the TGF-ß family of proteins. The recent milestone of dosing the first patient in the Phase 3 RENEW trial for Elritercept signifies progress in their clinical pipeline, triggering a $10 million payment under their global license agreement with Takeda. This development underscores Keros' commitment to advancing its therapeutic candidates through clinical trials, potentially enhancing its future revenue streams. Analyzing KROS's financial metrics, the company's P/E ratio is not applicable as it is still in the clinical stage and not yet profitable. Its EPS growth remains negative, reflecting the ongoing investment in R&D and clinical trials. Compared to industry peers like Rocket Pharmaceuticals and Krystal Biotech, Keros shows similar characteristics of high R&D expenditure and a focus on pipeline advancement rather than immediate profitability. Revenue forecasts for Keros are speculative at this point, heavily reliant on successful trial outcomes and subsequent regulatory approvals. Earnings Report and Expectations Upcoming earnings reports for Keros are anticipated to provide further insights into their financial health and clinical progress. Historically, the company has reported significant R&D expenditure, consistent with its business model as a clinical-stage biotech firm. Analyst consensus estimates suggest continued investment in clinical trials, with expectations for incremental revenue growth contingent on successful trial outcomes and potential partnerships or licensing agreements. The impact of these reports on the stock is likely to hinge on both clinical trial updates and financial spending efficiency. Sector Performance The biotechnology sector, encompassing companies like Keros, is characterized by high volatility and significant dependency on clinical trial outcomes and regulatory approvals. Currently, the sector is observing a mixed performance with some companies experiencing significant stock price increases following positive trial results, as seen with Rhythm Pharmaceuticals and Rocket Pharmaceuticals. This highlights the sector's potential for substantial returns amid inherent risks, as firms navigate through regulatory pathways and strive for successful therapeutic developments. - Funds were net buyers of $KROS during the previous reporting quarter. - Funds with large holdings in $KROS include: - Nantahala Capital Management LLC, MV: $15MM. Fund Rank: 67% www.nantahalapartners.com - OrbiMed Advisors LLC, MV: $10MM. Fund Rank: 55% www.orbimed.com - Alkeon Capital Management LLC, MV: $9MM. Fund Rank: 94% www.alkeoncapital.com - Redmile Group LLC, MV: $6MM. Fund Rank: 55% www.redmilegroup.com - PDT Partners LLC, MV: $3MM. New position. Fund Rank: 89% www.pdtpartners.com - Last 10 days performance: 4% - Last 30 days performance: 7% - Last 90 days performance: -2% Some of the latest news articles: - Title: KROS vs. EXAS: Which Stock Should Value Investors Buy Now? Publication Date: 7/28/2025 3:40:04 PM, Source: yahoo URL: https://finance.yahoo.com/news/kros-vs-exas-stock-value-154004166.html?.tsrc=rss - Title: RCKT Stock Up on FDA's RMAT Tag to Gene Therapy for Heart Failure Publication Date: 7/18/2025 3:28:00 PM, Source: yahoo URL: https://finance.yahoo.com/news/rckt-stock-fdas-rmat-tag-152800831.html?.tsrc=rss - Title: Keros Therapeutics Announces the First Patient Dosing in the Phase 3 RENEW Clinical Trial of Elritercept Publication Date: 7/17/2025 12:00:00 PM, Source: yahoo URL: https://finance.yahoo.com/news/keros-therapeutics-announces-first-patient-120000028.html?.tsrc=rss - Title: KRYS Begins Dosing With Gene Therapy in Rare Eye Disease, Stock Up Publication Date: 7/10/2025 4:10:00 PM, Source: yahoo Follow us on stocktwits.com and Substack (chessgmstocks.substack.com). Not a financial advice. Not a trading signal."

$KROS chat gpt's take on KROS share price: Final Perspective Your potential share price: $25/share in the base-case reflects pipeline potential with prudent discounting. $30/share in a bull-case accentuates clinical and strategic upside. This compares favorably to current market pricing which treats much of the pipeline as unvalued.

$KROS PT 15

$BMY's Reblozyl struggles in Phase III — what's next for this key drug? 🤔 The INDEPENDENCE study didn't meet its primary endpoint for RBC transfusion independence, yet BMY plans to discuss marketing applications with FDA & EMA. Meanwhile, competition heats up with $KROS's RENEW study milestone. Opportunity assessment here 👉 https://www.zacks.com/stock/news/2608173/will-reblozyl-enable-bmy-to-offset-the-impact-of-generic-competition?cid=sm-stocktwits-2-2608173-body-3312&ADID=SYND_STOCKTWITS_TWEET_2_2608173_BODY_3312

$KROS So let me get this straight: if I buy this now at $13.50, I’m going to get the special dividend of $9 but then my stock does go $4.50? And that $9 also gets taxed as income?

$KROS forming a nice tight range. Could break out soon.